Concurrent epirubicin and trastuzumab use increases complete pathological response rate without additional cardiotoxicity in patients with human epidermal growth factor receptor 2‐positive early breast cancer: A meta‐regression analysis
Cancer Medicine · 2024
DOI: 10.1002/cam4.70005 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Cancer Medicine, 2024. Verfasst von Ming-Han Yang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan. Hauptthemen laut MEDLINE: Epirubicin, Trastuzumab, Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Science and Technology Council, Ministry of Health and Welfare, Taiwan, Ministry of Health and Welfare.
Abstract (Originalsprache)
Background
Due to cardiotoxicity concerns, the concurrent use of epirubicin and trastuzumab has not been fully studied. This study aimed to examine the cardiotoxicity and pathological complete response (pCR) rate associated with the concurrent regimens in patients with human epidermal growth factor receptor 2 (HER2)‐positive early breast cancer (EBC).
Methods
We conducted a systematic search for relevant literature in the NCBI/PubMed, the Cochrane database, and international conference abstracts for phase II or III randomized controlled trials between January 1, 2000, and February 28, 2021, focusing on the concurrent regimens in patients with HER2‐positive EBC. To compare the risk of cardiotoxicity and the odds of the pCR rate, we performed linear meta‐regression analyses to investigate the effects of multiple covariates.
Results
We analyzed 7 neoadjuvant trials involving the concurrent use of epirubicin and trastuzumab with 1797 patients. The median cumulative dose of epirubicin used was 300 mg/m 2 , with a total of 96 reported adverse cardiac events. The concurrent regimens did not result in a significant increase in cardiotoxicity compared to nonconcurrent regimens (risk ratio [RR] = 1.18, 95% confidence interval [CI] = 0.68–2.05). Compared with nonconcurrent or non‐anthracycline‐containing regimens, concurrent regimens were associated with a significant increase in the pCR rate (odds ratio = 1.48, 95% CI = 1.04–2.12). The linear fixed‐effects meta‐regression analysis indicated that in trials including more patients with hormone receptor‐positive EBC, the RR of cardiotoxicity significantly increased with concurrent regimens, and the pCR rate became less significant.
Conclusions
The combination of trastuzumab and a low dose of epirubicin positively impacted the pCR rate without a significant increase in cardiotoxicity. We recommend exploring concurrent regimens for HR‐negative, HER2‐positive tumors to enhance pCR rates, with caution advised for HR‐positive tumors due to potential cardiotoxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan.
- Department of Surgery, National Taiwan University, Taipei, Taiwan.
- College of Medicine, National Taiwan University, Taipei, Taiwan.
- Graduate Institute of Clinical Medicine and School of Nursing, College of Medicine, National Taiwan University, Taipei, Taiwan.
- Statistical Consulting Clinic, International-Harvard (I-H) Statistical Consulting Company, Taipei, Taiwan.
- Department of Oncology, National Taiwan University Cancer Center, Taipei, Taiwan.
ORCID-Profile: I-Chun Chen, Tom Wei-Wu Chen, Yen-Shen Lu
Förderung
- National Science and Technology Council
- Ministry of Health and Welfare, Taiwan
- Ministry of Health and Welfare
Zitieren
APA
Yang, M. H., Huang, C. S., Chang, D. Y., Hu, F. C., Huang, S. M., Huang, P. H., Chen, I. C., Chen, T. W., Lin, C. H., & Lu, Y. S. (2024). Concurrent epirubicin and trastuzumab use increases complete pathological response rate without additional cardiotoxicity in patients with human epidermal growth factor receptor 2‐positive early breast cancer: A meta‐regression analysis. Cancer Medicine. https://doi.org/10.1002/cam4.70005
Vancouver
Yang MH, Huang CS, Chang DY, Hu FC, Huang SM, Huang PH, et al. Concurrent epirubicin and trastuzumab use increases complete pathological response rate without additional cardiotoxicity in patients with human epidermal growth factor receptor 2‐positive early breast cancer: A meta‐regression analysis. Cancer Medicine. 2024. doi:10.1002/cam4.70005
BibTeX
@article{Yang2024,
author = {Yang, Ming-Han and Huang, Chiun-Sheng and Chang, Dwan-Ying and Hu, Fu-Chang and Huang, Shu-Min and Huang, Po-Hsiang and Chen, I-Chun and Chen, Tom Wei-Wu and Lin, Ching-Hung and Lu, Yen-Shen},
title = {Concurrent epirubicin and trastuzumab use increases complete pathological response rate without additional cardiotoxicity in patients with human epidermal growth factor receptor 2‐positive early breast cancer: A meta‐regression analysis},
journal = {Cancer Medicine},
year = {2024},
doi = {10.1002/cam4.70005}
}
EUVIMED